Vinton Cheng

Vinton Cheng


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TSThomas Starkey
Thomas Starkey
MIMaria C. Ionescu
Maria C. Ionescu
MTMichael Tilby
Michael Tilby
MLMartin Little
Martin Little
EBEmma Burke
Emma Burke
LLLennard Y. W. Lee
Lennard Y. W. Lee
Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission.

25 April 2023 in International Journal of Cancer
Verified
Journal Article
Open access
SKSiddarth Kannan
Siddarth Kannan
VCVinton Cheng
Vinton Cheng
Breast cancer brain metastasis (BCBM) is rapidly becoming an impediment to continuing survival gains seen in breast cancer patients. Drug delivery across the blood‐brain barrier is the main issue hindering systemic therapy against BCBM. This review details recent advances in nanoparticle (NP) drug delivery systems to target BCBM. Their primary benefits are: enhanced circulating and intra‐BCBM drug biodistribution, BCBM targeting through NP functionalization, opportunities for gene manipulation and their theragnostic applications. Multiple NPs have been synthesized to deliver therapeutic HER2 blockade, which is particularly important given HER2‐positive breast cancer's tendency to form BCBM. Finally, we review the clinical context in which NP‐based therapeutics have been investigated in BCBM patients. While a breakthrough in improving patient outcomes remain awaited, these clinical trials represent positive steps in the changing attitude towards BCBM as a treatable illness. Although multiple challenges remain in the clinical translation of BCBM‐directed NP therapies, ongoing research in the field offers promising avenues for novel targeting of this devastating disease.

2 August 2024 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
VCVinton Cheng
Vinton Cheng
RHRichard Heywood
Richard Heywood
RZRasheed Zakaria
Rasheed Zakaria
RBRebecca Burger
Rebecca Burger
KZKieran Zucker
Kieran Zucker
CPCarlo Palmieri
Carlo Palmieri
Background: Recent studies have challenged the notion that patients with brain metastasis (BM) or leptomeningeal metastasis (LM) should be excluded from systemic therapy clinical trials. This scoping study summarizes the BM/LM clinical studies published between 2010 and 2023. Methods: MEDLINE, CINAHL, CAB Abstracts, PsycINFO, Cochrane Library, HINARI, International Pharmaceutical Abstracts, PubMed, Scopus, Web of Science, and EMBASE electronic databases were searched on June 21, 2021. An updated search was performed on February 21, 2023. Eligible studies investigated a therapeutic intervention in solid tumor patients with BM and/or LM and reported a patient outcome. Extracted study-level data, including study type, publication date, geographical location, number of BM/LM patients in the study, primary tumor type, and type of therapeutic intervention, were collected. Results: 4921 unique studies were eligible for analysis. The key finding is that BM/LM clinical research is expanding globally, both in observational studies and clinical trials. Despite the shift over time toward a higher proportion of systemic therapy trials, the majority still do not include patients with symptomatic disease and lack reporting of BM/LM-specific endpoints. Globally, there has been a trend to more international collaboration in BM/LM clinical studies. Conclusions: Our analysis of the BM/LM literature charts the evolving landscape of studies involving this previously excluded population. Given the increasing clinical research activity, particularly involving late-stage systemic therapy trials, it is imperative that due consideration is given to the intracranial activity of new investigational agents. Wider adoption of standardized reporting of intracranial-specific endpoints will facilitate the evaluation of relative intracranial efficacy.

23 May 2025 in Cancer Epidemiology
Verified
Journal Article
Open access
JDJiawen Dong
Jiawen Dong
TSThomas Starkey
Thomas Starkey
VCVinton Cheng
Vinton Cheng
JCJames Clark
James Clark
David James PinatoDavid James Pinato
David James Pinato
LLLennard YW Lee
Lennard YW Lee
Obesity is a major risk factor for many cancers. Glucagon-like peptide-1 receptor agonists (GLP-1RA) have emerged as highly effective agents for weight loss. There is a lack of published modelling studies describing the broader implications of GLP-1RA-induced weight loss on cancer incidence. A Markov state-transition model was devised to evaluate the impact of GLP-1RA-induced weight loss on future cancer incidence in adults. Contemporary data on weight distribution, cancer incidence, and body mass index (BMI)-associated cancer risk were integrated into the model. Two scenarios were assessed, GLP-1RAs were made available to all people with obesity (BMI>30) or only those with severe obesity (BMI>35). New cancer cases were simulated over a decade. Our simulation within a closed cohort indicated that GLP-1RA-induced weight loss would lead to a marked decrease in cancer cases over 10 years in adults. If GLP-1RAs were made available for all people with obesity and 50 % of people with obesity moved into a lower BMI category, there was a simulated reduction in cumulative cancer cases of 21,443. If access to GLP-1RAs was restricted to people with severe obesity and 50 % of people with severe obesity moved into a lower BMI category, there was a simulated reduction in cumulative cancer cases of 7476. This effect was greatest for uterine, kidney, liver and colon cancer. Targeted weight control measures using GLP-1RAs could reduce new cancer cases. Based on our models, the potential risk of thyroid cancer is balanced by a reduction in other cancer types. This modelling study shows for the first time that implementing effective weight loss programmes could enhance the health of the population over the next decade through a reduction in cancer cases.

5 June 2020 in Clinical Oncology
Verified
Journal Article
Open access
PDF file
JBJ. Best
J. Best
TST. Starkey
T. Starkey
ACA. Chatterjee
A. Chatterjee
DFD. Fackrell
D. Fackrell
LPL. Pettit
L. Pettit
LLL.Y.W. Lee
L.Y.W. Lee
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: T. Starkey, A. Olsson-Brown, V. Cheng, D.J. Hughes, A.J.X. Lee, K. Purshouse, R. Arnold, C. Palles, S. Sivakumar, J.-B. Cazier and L.Y.W. Lee comprise part of the UK Coronavirus Monitoring Project team, donating time and resources to support the project. No other conflicts of interest are declared.

4 October 2026 in Clinical Medicine
Verified
Journal Article
Open access
MEMelyda
Melyda
AOAhmad Ozair
Ahmad Ozair
SLSean E.H. Lau
Sean E.H. Lau
IGIrene S. Guterman
Irene S. Guterman
FFFaisal Fa’AK
Faisal Fa’AK
VCVinton Cheng
Vinton Cheng